Every S-1 that Envoy Medical (COCH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The company states that the rest of the registration statement is unchanged and has been omitted from this amendment.
The amendment primarily adds or updates exhibits, including forms of warrants and a securities purchase agreement related to the planned offering, various employment and incentive plan documents, debt and forward purchase agreements, and an engagement letter with H.C. Wainwright & Co., LLC. Signature pages confirm authorization by the chief executive officer and directors.
Envoy Medical, Inc. is conducting a primary offering registering up to 47,169,811 shares of Class A common stock, multiple series of accompanying warrants, and up to 125,943,394 shares issuable upon exercise of those warrants. The company is selling the stock and associated Series A-1 and Series A-2 common warrants on a reasonable best efforts basis through H.C. Wainwright at an assumed combined public offering price of $0.53 per share and accompanying warrants. Pre-funded warrants are available for investors constrained by 4.99% or 9.99% beneficial ownership limits, and placement agent warrants cover up to 3,301,886 additional shares. Envoy estimates net proceeds of approximately $23.0 million, expects continued net losses as it advances pivotal trials and FDA review of its fully implanted Acclaim cochlear implant, and warns of Nasdaq listing risks, going-concern uncertainty, and substantial dilution for existing shareholders.
Envoy Medical, Inc. filed a Form S-1 for a primary, reasonable best efforts offering of Class A Common Stock and pre-funded warrants, with all net proceeds going to the company. The securities will be priced with investors and the placement agent based on market conditions, and pre-funded warrants are structured so investors do not exceed 4.99% or 9.99% ownership limits. Envoy had 28,934,960 shares of Common Stock outstanding as of December 15, 2025.
The company is a hearing health developer focused on its fully implanted Acclaim cochlear implant, which has FDA Breakthrough Device Designation and is in a pivotal clinical trial whose second stage was cleared by the FDA on October 3, 2025. Envoy reported net losses of $17.2 million for the nine months ended September 30, 2025 and has an accumulated deficit of $305.7 million, and its auditors have raised substantial doubt about its ability to continue as a going concern. Recent registered direct offerings in September and October 2025 raised about $6.5 million in gross proceeds, and the company faces Nasdaq compliance pressures related to both minimum market value of listed securities and minimum bid price.
Envoy Medical, Inc. filed a resale Form S-1 registering up to 15,116,472 shares of Class A Common Stock for selling stockholders. These are issuable upon exercise of previously issued warrants: 5,725,206 September Private Placement Warrant shares at $1.31, 9,022,572 October Private Placement Warrant shares at $1.33, 143,130 September Placement Agent Warrant shares at $1.6375, and 225,564 October Placement Agent Warrant shares at $1.6625.
The company will not receive proceeds from share resales. If all warrants are exercised for cash, Envoy Medical would receive approximately $20.1 million. September Private Placement and Placement Agent Warrants become exercisable upon stockholder approval; the October Private Placement and Placement Agent Warrants were immediately exercisable and expire two years after the registration statement’s effective date, subject to outside dates in 2030.
Recent updates note completed Stage 1 implantation and activation of 10 patients in the pivotal Acclaim cochlear implant trial, with FDA approval to proceed to Stage 2 (adding 46 participants). The company also disclosed prior registered offerings in September 2025 (~$2.5M) and October 2025 (~$4.0M), and ongoing Nasdaq compliance matters.